Allon Therapeutics

PPD adds Michael Gold to neuroscience team

Thursday, September 10, 2015

Pharmaceutical Product Development (PPD) has announced that Michael Gold, M.D., has joined PPD’s neuroscience team to serve as vice president of global product development, strengthening the company’s ability to help biopharmaceutical clients manage the complex world of nervous system disorders and deliver therapies more efficiently and cost-effectively.

[Read More]

Allon Therapeutics enrolls for frontal dementia trial

Thursday, May 19, 2011

Allon Therapeutics is currently enrolling patients in a phase 2/3 study for its lead neuroprotective drug candidate, davunetide, a treatment for progressive supranuclear palsy (PSP), a form of frontotemporal dementia (FTD). Allon has completed two phase 2a human efficacy studies for davunetide in patients with amnesic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease, and in patients with cognitive impairment associated with schizophrenia (CIAS).

[Read More]

eClinical Round-Up

Tuesday, July 1, 2008

During the DIA 2008 Annual Meeting held in Boston, Phase Forward announced it formed an alliance with AG Mednet to streamline the process of transporting medical imaging, such as MRIs, CAT scans and ultrasounds. The alliance calls for the combining of InForm, Phase Forward’s trial management system, and AG Mednet’s imaging transport network for better tracking and management of patient images in real time from sites to imaging experts. “Clinical trial sponsors need a way to transport patient images more quickly and efficiently for less cost, and a real-time capability to track and manage these images,” said Martin Young Phase Forward’s vice president of corporate development and marketing.

[Read More]